The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 

Stephanos J. Hadziyannis

Department of Medicine and Hepatology

Henry Dunant Hospital

National and Kapodistrian University of Athens

Athens

Greece

[email]@ath.forthnet.gr

Name/email consistency: high

 
 
 
 
 
 
 

Affiliations

  • Department of Medicine and Hepatology, Henry Dunant Hospital, National and Kapodistrian University of Athens, Athens, Greece. 2011 - 2012
  • Liver Research Unit of Athens University, Evgenidion Hospital, Athens, Attica, Greece. 1999 - 2012

References

  1. Sustained responses and loss of HBsAg in HBeAg-negative patients with chronic hepatitis B who stop long-term treatment with adefovir. Hadziyannis, S.J., Sevastianos, V., Rapti, I., Vassilopoulos, D., Hadziyannis, E. Gastroenterology (2012) [Pubmed]
  2. Commentary: combination therapy with two nucleos(t)ide analogues in chronic hepatitis B. Hadziyannis, S.J. Aliment. Pharmacol. Ther. (2012) [Pubmed]
  3. Commentary: HBsAg levels as predictor of sustained response to peg interferon in HBeAg-negative chronic hepatitis B. Hadziyannis, S.J. Aliment. Pharmacol. Ther. (2012) [Pubmed]
  4. Milestones and perspectives in viral hepatitis B. Hadziyannis, S.J. Liver Int. (2011) [Pubmed]
  5. Limitations of retrospective IL28B polymorphisms and IP-10 real life studies in hepatitis C. Hadziyannis, S.J. Aliment. Pharmacol. Ther. (2011) [Pubmed]
  6. Telbivudine in the treatment of chronic hepatitis B. Hadziyannis, S.J., Vassilopoulos, D. Expert. Rev. Gastroenterol. Hepatol (2008) [Pubmed]
  7. Treatment paradigms on hepatitis B e antigen-negative chronic hepatitis B patients. Hadziyannis, S.J. Expert. Opin. Investig. Drugs (2007) [Pubmed]
  8. Unrevealing the natural course of the so-called "inactive HBsAg or HBV carrier state". Hadziyannis, S.J. Hepatology. International (2007) [Pubmed]
  9. New developments in the treatment of chronic hepatitis B. Hadziyannis, S.J. Expert. Opin. Biol. Ther (2006) [Pubmed]
  10. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Hadziyannis, S.J., Tassopoulos, N.C., Heathcote, E.J., Chang, T.T., Kitis, G., Rizzetto, M., Marcellin, P., Lim, S.G., Goodman, Z., Ma, J., Brosgart, C.L., Borroto-Esoda, K., Arterburn, S., Chuck, S.L. Gastroenterology (2006) [Pubmed]
  11. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B. Hadziyannis, S.J., Tassopoulos, N.C., Heathcote, E.J., Chang, T.T., Kitis, G., Rizzetto, M., Marcellin, P., Lim, S.G., Goodman, Z., Ma, J., Arterburn, S., Xiong, S., Currie, G., Brosgart, C.L. N. Engl. J. Med. (2005) [Pubmed]
  12. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Hadziyannis, S.J., Sette, H., Morgan, T.R., Balan, V., Diago, M., Marcellin, P., Ramadori, G., Bodenheimer, H., Bernstein, D., Rizzetto, M., Zeuzem, S., Pockros, P.J., Lin, A., Ackrill, A.M. Ann. Intern. Med. (2004) [Pubmed]
  13. Adefovir dipivoxil in the treatment of chronic hepatitis B virus infection. Hadziyannis, S.J., Papatheodoridis, G.V. Expert. Rev. Anti. Infect. Ther (2004) [Pubmed]
  14. Emerging treatments in chronic hepatitis B. Hadziyannis, S.J., Papatheodoridis, G.V. Expert. Opin. Emerg. Drugs (2004) [Pubmed]
  15. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. Hadziyannis, S.J., Tassopoulos, N.C., Heathcote, E.J., Chang, T.T., Kitis, G., Rizzetto, M., Marcellin, P., Lim, S.G., Goodman, Z., Wulfsohn, M.S., Xiong, S., Fry, J., Brosgart, C.L. N. Engl. J. Med. (2003) [Pubmed]
  16. Treatment of HBeAg-negative chronic hepatitis B. Hadziyannis, S.J., Papatheodoridis, G.V., Vassilopoulos, D. Semin. Liver Dis. (2003) [Pubmed]
  17. Peginterferon-alpha2a (40 kDa) for chronic hepatitis C. Hadziyannis, S.J., Papatheodoridis, G.V. Expert. Opin. Pharmacother (2003) [Pubmed]
  18. Treatment of HBeAg negative chronic hepatitis B with new drugs (adefovir and others). Hadziyannis, S.J., Papatheodoridis, G.V. J. Hepatol. (2003) [Pubmed]
  19. Hepatitis B e antigen-negative chronic hepatitis B. Hadziyannis, S.J., Vassilopoulos, D. Hepatology (2001) [Pubmed]
  20. Immunopathogenesis of hepatitis B e antigen negative chronic hepatitis B infection. Hadziyannis, S.J., Vassilopoulos, D. Antiviral Res. (2001) [Pubmed]
  21. Interferon treatment with or without oral ganciclovir in HBeAg-negative chronic hepatitis B: a randomized study. Hadziyannis, S., Alexopoulou, A., Papakonstantinou, A., Petraki, K., Manesis, E. J. Viral Hepat. (2000) [Pubmed]
  22. Efficacy of long-term lamivudine monotherapy in patients with hepatitis B e antigen-negative chronic hepatitis B. Hadziyannis, S.J., Papatheodoridis, G.V., Dimou, E., Laras, A., Papaioannou, C. Hepatology (2000) [Pubmed]
  23. Long-term outcome of chronic hepatitis C treated with interferon. Hadziyannis, S.J., Papatheodoridis, G.V. Ital. J. Gastroenterol. Hepatol (1999) [Pubmed]
 
WikiGenes - Universities